Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial
Posted inClinical Updates Wellness & Lifestyle

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial strain and cardiac biomarkers suggest a potential role in cardioprotection.
Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial
Posted inClinical Updates Wellness & Lifestyle

Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial

The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients with both abnormalities face higher hyperkalemia risk.